LONG-TERM OUTCOMES OF SPLENECTOMY FOR PATIENTS WITH β- THALASSEMIA MAJOR
Main Article Content
Keywords
β-thalassemia major, splenectomy, transfusion requirements, complications, quality of life, chronic anemia, hematological disorders
Abstract
Individuals diagnosed with β-thalassemia major frequently deal with problems
related to splenomegaly and persistent anaemia. In order to address these issues, this study explores
the long-term effects of splenectomy as a therapeutic strategy.
Methods: A retrospective cohort study of 150 patients with β-thalassemia major who underwent
splenectomy was carried out in the department of surgery at MTI, Mardan Medical Complex,
Mardan, Pakistan during the years between 2018 and 2022. The study evaluated improvements in
quality of life, incidence of complications following splenectomy, and changes in transfusion
requirements.
Results: Our results show a considerable and statistically significant decrease in the need for
transfusions after splenectomy, especially in extremely transfusion-dependent patients (p < 0.001).
The study also shows that, in line with previous research, the incidence of sequelae, such as sepsis
and thrombocytosis, was below acceptable bounds. Subjective evaluations showed a significant
increase in overall quality of life, which was corroborated by lower pain and exhaustion scores (p
< 0.001).
References
2. Isa MM, Thayeb A, Yani A, Hutagalung MB. Post total splenectomy outcome in thalassemia patients. Bali Medical Journal. 2019 Dec 31;8(3):947-50.
3. Zahira AF, Wasono AR, Yudho SU, Bintoro HK. The Role of Splenectomy in The Treatment of β-Thalassemia Major Patients: A Literature Review. The Role of Splenectomy in The Treatment of β-Thalassemia Major Patients: A literature review. 2022 Dec 27;115(1):6-.
4. Dedeoglu S, Bornaun H. Pulmonary hypertension in children with β thalassemia major, are splenectomy and high-ferritin levels related or not?. Journal of Pediatric Hematology/Oncology. 2017 May 1;39(4):259-65.
5. Al-Salem AH. Splenectomy for children with Thalassemia: Total or partial splenectomy, open or laparoscopic splenectomy. Journal of Pediatric Hematology/Oncology. 2016 Jan 1;38(1):1-4.
6. Jean-Mignard E, De Luna G, Pascal L, Agouti I, Thuret I. SARS-CoV-2 infection in patients with β-thalassemia: the French experience. Transfusion Clinique et Biologique. 2022 Feb 1;29(1):70-4.
7. Yang K, Wu Y, Zhou Y, Long B, Lu Q, Zhou T, Wang L, Geng Z, Yin X. Thalidomide for patients with β-thalassemia: a multicenter experience. Mediterranean journal of hematology and infectious diseases. 2020;12(1).
8. Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood, the Journal of the American Society of Hematology. 2018 Oct 25;132(17):1781-91.
9. Origa R. β-Thalassemia. Genetics in Medicine. 2017 Jun 1;19(6):609-19.
10. Piga A, Longo F, Gamberini MR, Voskaridou E, Ricchi P, Caruso V, Pietrangelo A, Zhang X, Shetty JK, Attie KM, Tartaglione I. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia. Therapeutic Advances in Hematology. 2022 Dec;13:20406207221134404.
11. Sanpakit K, Narkbunnam N, Buaboonnam J, Takpradit C, Viprakasit V, Pongtanakul B. Impact of splenectomy on outcomes of hematopoietic stem cell transplantation in pediatric patients with transfusion‐dependent thalassemia. Pediatric Blood & Cancer. 2020 Sep;67(9):e28483.
12. Ayyash H, Sirdah M. Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza Strip: A cross-sectional study. International journal of health sciences. 2018 Nov;12(6):18.
13. Haghpanah S, Vahdati S, Karimi M. Comparison of quality of life in patients with β-Thalassemia intermedia and β-Thalassemia major in Southern Iran. Hemoglobin. 2017 May 4;41(3):169-74.
14. Correia JG, Moreira N, Almeida CE, Reis LS. Partial Splenectomy in the treatment of an adult with β thalassemia intermedia: A case report. International journal of surgery case reports. 2017 Jan 1;41:446-9.
15. Psatha N, Reik A, Phelps S, Zhou Y, Dalas D, Yannaki E, Levasseur DN, Urnov FD, Holmes MC, Papayannopoulou T. Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with β-thalassemia major. Molecular Therapy-Methods & Clinical Development. 2018 Sep 21;10:313-26.
16. Ekwattanakit S, Siritanaratkul N, Viprakasit V. A prospective analysis for prevalence of complications in Thai nontransfusion‐dependent Hb E/β‐thalassemia and α‐thalassemia (Hb H disease). American Journal of Hematology. 2018 May;93(5):623-9.
17. Mehta R, Kabrawala M, Nandwani S, Desai P, Bhayani V, Patel S, Parekh V. Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with β-thalassemia major. Journal of clinical and experimental hepatology. 2018 Mar 1;8(1):3-6.
18. Taher AT, Bou-Fakhredin R, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology. 2021 Oct 3;14(10):897-909.
19. Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood reviews. 2019 Sep 1;37:100588.
20. De Sanctis V, Elsedfy H, Soliman AT, Elhakim IZ, Soliman NA, Elalaily R, Kattamis C. Endocrine profile of β-thalassemia major patients followed from childhood to advanced adulthood in a tertiary care center. Indian journal of endocrinology and metabolism. 2016 Jul;20(4):451.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.